These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
867 related articles for article (PubMed ID: 16103469)
1. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Eddy DM; Schlessinger L; Kahn R Ann Intern Med; 2005 Aug; 143(4):251-64. PubMed ID: 16103469 [TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE; Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451 [TBL] [Abstract][Full Text] [Related]
3. Summaries for patients. The outcomes and costs of diabetes prevention with a diet and exercise program or metformin: a computer model. Ann Intern Med; 2005 Aug; 143(4):I22. PubMed ID: 16103465 [No Abstract] [Full Text] [Related]
4. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Prevention Program Research Group Diabetes Care; 2003 Sep; 26(9):2518-23. PubMed ID: 12941712 [TBL] [Abstract][Full Text] [Related]
5. Evaluating the cost-effectiveness of lifestyle modification versus metformin therapy for the prevention of diabetes in Singapore. Png ME; Yoong JS PLoS One; 2014; 9(9):e107225. PubMed ID: 25203633 [TBL] [Abstract][Full Text] [Related]
6. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Palmer AJ; Roze S; Valentine WJ; Spinas GA; Shaw JE; Zimmet PZ Clin Ther; 2004 Feb; 26(2):304-21. PubMed ID: 15038953 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of a Stepwise Approach vs Standard Care for Diabetes Prevention in India. Islek D; Weber MB; Ranjit Mohan A; Mohan V; Staimez LR; Harish R; Narayan KMV; Laxy M; Ali MK JAMA Netw Open; 2020 Jul; 3(7):e207539. PubMed ID: 32725244 [TBL] [Abstract][Full Text] [Related]
8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
9. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis. Palmer AJ; Tucker DM Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888 [TBL] [Abstract][Full Text] [Related]
10. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Avenell A; Broom J; Brown TJ; Poobalan A; Aucott L; Stearns SC; Smith WC; Jung RT; Campbell MK; Grant AM Health Technol Assess; 2004 May; 8(21):iii-iv, 1-182. PubMed ID: 15147610 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review. Zhou X; Siegel KR; Ng BP; Jawanda S; Proia KK; Zhang X; Albright AL; Zhang P Diabetes Care; 2020 Jul; 43(7):1593-1616. PubMed ID: 33534726 [TBL] [Abstract][Full Text] [Related]
12. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Prevention Program Research Group Diabetes Care; 2012 Apr; 35(4):723-30. PubMed ID: 22442395 [TBL] [Abstract][Full Text] [Related]
13. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations]. Flórez H Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072 [TBL] [Abstract][Full Text] [Related]
14. Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation. Thomas C; Sadler S; Breeze P; Squires H; Gillett M; Brennan A BMJ Open; 2017 Aug; 7(8):e014953. PubMed ID: 28827235 [TBL] [Abstract][Full Text] [Related]
15. Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000. Icks A; Rathmann W; Haastert B; Gandjour A; Holle R; John J; Giani G; Diabet Med; 2007 May; 24(5):473-80. PubMed ID: 17381502 [TBL] [Abstract][Full Text] [Related]
16. Achievable cost saving and cost-effective thresholds for diabetes prevention lifestyle interventions in people aged 65 years and older: a single-payer perspective. Anderson JM J Acad Nutr Diet; 2012 Nov; 112(11):1747-54. PubMed ID: 23102174 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective. Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176 [TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Herman WH Clin Diabetes Endocrinol; 2015; 1():9. PubMed ID: 28702228 [TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada. Caro JJ; Getsios D; Caro I; Klittich WS; O'Brien JA Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090 [TBL] [Abstract][Full Text] [Related]